CA3075713A1 - Inflammatory biomarkers for predicting responsiveness to fgf-18 compound - Google Patents

Inflammatory biomarkers for predicting responsiveness to fgf-18 compound Download PDF

Info

Publication number
CA3075713A1
CA3075713A1 CA3075713A CA3075713A CA3075713A1 CA 3075713 A1 CA3075713 A1 CA 3075713A1 CA 3075713 A CA3075713 A CA 3075713A CA 3075713 A CA3075713 A CA 3075713A CA 3075713 A1 CA3075713 A1 CA 3075713A1
Authority
CA
Canada
Prior art keywords
fgf
treatment
compound
subject
cartilage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3075713A
Other languages
English (en)
French (fr)
Inventor
Christoph H. Ladel
Hans Guehring
Anne-Christine Bay-Jensen
Morten Karsdal
Per Qvist
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA3075713A1 publication Critical patent/CA3075713A1/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3075713A 2017-09-29 2018-09-28 Inflammatory biomarkers for predicting responsiveness to fgf-18 compound Pending CA3075713A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17194169 2017-09-29
EP17194169.3 2017-09-29
EP18169317 2018-04-25
EP18169317.7 2018-04-25
PCT/EP2018/076391 WO2019063756A1 (en) 2017-09-29 2018-09-28 INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND

Publications (1)

Publication Number Publication Date
CA3075713A1 true CA3075713A1 (en) 2019-04-04

Family

ID=63722379

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075713A Pending CA3075713A1 (en) 2017-09-29 2018-09-28 Inflammatory biomarkers for predicting responsiveness to fgf-18 compound

Country Status (16)

Country Link
US (2) US11467169B2 (https=)
EP (1) EP3688468B1 (https=)
JP (1) JP7418324B2 (https=)
CN (1) CN111164429B (https=)
AU (1) AU2018343980B2 (https=)
CA (1) CA3075713A1 (https=)
DK (1) DK3688468T3 (https=)
ES (1) ES2918249T3 (https=)
HR (1) HRP20220737T1 (https=)
HU (1) HUE058848T2 (https=)
IL (1) IL273574B2 (https=)
LT (1) LT3688468T (https=)
PL (1) PL3688468T3 (https=)
RS (1) RS63292B1 (https=)
SI (1) SI3688468T1 (https=)
WO (1) WO2019063756A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339002A1 (en) 1996-10-16 2011-06-29 ZymoGenetics, Inc. Fibroblast growth factor homologs
ES2493840T3 (es) 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
AU2003287697A1 (en) 2002-11-08 2004-06-03 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US8224579B2 (en) 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
HRP20120643T1 (hr) 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
JP2009257842A (ja) 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス, インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
AU2013301607B2 (en) 2012-08-06 2018-10-18 Merck Patent Gmbh Prognosis biomarkers in cartilage disorders
CN104736723B (zh) * 2012-08-06 2017-10-31 默克专利有限公司 用于预测对fgf‑18化合物的响应性的遗传标记
CA2931978A1 (en) * 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
KR102622290B1 (ko) 2013-12-24 2024-01-05 아레스 트레이딩 에스.아. 크실로글루칸 겔 중의 fgf-18 제형물
ES2806026T3 (es) 2013-12-24 2021-02-16 Ares Trading Sa Formulación de FGF-18 en hidrogeles de alginato/colágeno
HUE040350T2 (hu) * 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fgf−18を含むインプラント
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Also Published As

Publication number Publication date
RS63292B1 (sr) 2022-06-30
HRP20220737T1 (hr) 2022-09-02
IL273574B1 (en) 2024-09-01
AU2018343980A1 (en) 2020-04-02
CN111164429B (zh) 2024-08-09
AU2018343980B2 (en) 2025-04-10
ES2918249T3 (es) 2022-07-14
EP3688468B1 (en) 2022-03-16
LT3688468T (lt) 2022-06-27
US12332250B2 (en) 2025-06-17
US20230258659A1 (en) 2023-08-17
PL3688468T3 (pl) 2022-07-18
US11467169B2 (en) 2022-10-11
IL273574B2 (en) 2025-01-01
SI3688468T1 (sl) 2022-08-31
WO2019063756A1 (en) 2019-04-04
IL273574A (en) 2020-05-31
JP7418324B2 (ja) 2024-01-19
EP3688468A1 (en) 2020-08-05
CN111164429A (zh) 2020-05-15
DK3688468T3 (da) 2022-06-20
JP2020535423A (ja) 2020-12-03
HUE058848T2 (hu) 2022-09-28
US20210231680A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
US12332250B2 (en) Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US12332251B2 (en) Metabolic biomarkers for predicting responsiveness to FGF-18 compound
US20260102469A1 (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241025

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250303

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250707

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250725

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250725

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250901

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250901